MEETUP - STARTUP SC 28º MEETUP STARTUPSC 2ª EDIÇÃO CHAPECÓ

Em 13 de Agosto de 2018, acadêmicos dos Cursos de Administração, Ciências Contábeis e NAF, da Unoesc Chapecó juntamente com professores e a coordenadora dos Cursos professor Carla Fabiana Cazella, participam do Meetup Programa StartupSC, projeto que vem sendo desenvolvido e fortalecendo as Startups em todo o Estado Catarinense.Para os alunos e professores, foi uma noite especial pois foi possível vislumbrar de grandes empreendedores, investidores, que cada vez mais vem impactando positivamente a matriz econômica de Santa Catarina.Na oportunidade,  foram apresentadas curtas palestras  e muitas dicas, técnicas e inspiração para desenvolver o próprio negócio.Para a coordenadora, professora Carla Cazella programas como esses abrilhantam cada vez mais o nosso conhecimento e de nossos alunos, e com esses startups e possível fazer muitos networking

Plan de negocio para una aplicaci?n utilitaria que junta los descuentos que las empresas otorgan a sus clientes

En el Per? los bancos, compa??as de telefon?a y de seguro, entre otros, otorgan a sus clientes programas de lealtad, a los cuales se accede a trav?s de aplicaciones, sin embargo, un gran porcentaje de los clientes no usan dichos programas, por desconocimiento o porque descargar tantas aplicaciones, genera problemas t?cnicos, en los smartphones. Ante tal situaci?n el presente proyecto desarrolla una aplicaci?n llamada ?ypagamenos? que junta, muestra y compara los descuentos que otorgan los programas de lealtad, a cada cliente de forma individual y a los cuales acceder?an con solo ingresar el n?mero de su DNI; as? el uso de los descuentos y beneficios ser?a m?s sencillo y efectivo. ?Ypagamenos? tendr? una versi?n gratuita con publicidad y otra versi?n pagada sin publicidad y con mayores atributos y estar? disponible en dispositivos con sistemas operativos Android y iOS. Con ?ypagamenos? se conseguir? que las empresas de banca y telefon?a, con quienes inicialmente se suscribir?a convenios de exclusividad, no s?lo logren que sus clientes usen los programadas de lealtad sino tambi?n la fidelizaci?n de los mismos, mayor alcance y conversi?n y por parte del cliente se lograr? que use todos los descuentos que ya tiene y cuando m?s le convenga

Cryptosporidium spp. in Aratinga jandaia, Diopsittaca nobilis and Pionus menstruus in Brazil

Background: Cryptosporidium is an important protozoan in public health and veterinary medicine that often causes diarrhea in an array of hosts in developed/developing countries. Infection of the gastrointestinal system is the most common, but the respiratory system and other sites can also be affected, especially in birds and immunocompromised individuals. Transmission occurs through ingestion or inhalation of oocysts. The number of wild animals, including those in the class of birds, infected with this parasite has grown in recent years. This study aimed to report parasitism by Cryptosporidium spp. in captive-raised birds of family Psittacidae at the Rio City Zoo in Rio de Janeiro, Brazil.Materials, Methods & Results: Thirty-three pools of fecal samples of the species Amazona aestiva, Amazona amazonica, Anodorhynchus hyacinthinus, Ara auricollis, Ara canga, Ara glaucogularis, Ara macao, Ara manilapa, Ara maracana, Ara rubrogenys, Aratinga erythrogenys, Aratinga cactorum, Aratinga auerea, Aratinga mitrata, Aratinga auricapilla, Aratinga jandaia, Aratinga wagleri, Aratinga leucophthalmus, Brotogeris acuticaudata, Cynoliseus patagonus, Caracopsis vasa, Diopsittaca nobilis, Graydidascalus brachyurus, Muopsitta monachus, Nangayus nenday, Pionites melancephala, Pionites leucogaster, Pionus menstruus, Pionus chalcopteus, Pionus maxiliani, Pyrrhura perlata, Pyrrhura leucotis, and Triclharia malachitacea, kept in separate enclosures, were analyzed using Enzyme-linked Immunosorbent Assay (ELISA) for detection of parasitic antigens. Quantitative Polymerase Chain Reaction (qPCR) was conducted in order to identify the species Cryptosporidium in the positive samples targeting the small subunit ribosomal RNA gene (SSU rRNA), followed by sequencing and analysis of the DNA amplicons. Cryptosporidium spp. antigen was detected in three (9%) of the thirtythree pools assessed, corresponding to the following species of family Psittacidae: Jandaya parakeet (Aratinga jandaya), Red-shouldered macaw (Diopsittaca nobilis), and Blue-headed parrot (Pionus menstruus). Positivity of the three samples was confirmed by qPCR analysis, but it was not possible to identify the species of Cryptosporidium by this technique.Discussion: Zoonotic diseases, such as cryptosporidiosis, have been reported in wild and captive-bred animals worldwide. Several species of the class of birds are parasitized by Cryptosporidium spp. Infection in order Psittaciformes has been described in some species raised in captivity in Brazil; however, no reports of Cryptosporidium spp. infecting the following species of order Psittaciformes: Jandaya parakeet (Aratinga jandaia), Red-breasted macaw (Diopsittaca nobilis), and Blue-headed parrot (Pionus menstrus), were found in the specific scientific literature. The present study detected infection by Cryptosporidium spp. in three species of order Psittaciformes using ELISA and confirmed the positivity of the samples by qPCR, but the species of Cryptosporidium could not be identified. These infected birds should be carefully investigated, with identification of the species and analysis of their zoonotic potential, because they can be sources of environmental contamination and infection for the caregivers, visitors, and other animals of the Zoo. This is the first report of parasitism by Cryptosporidium spp. in these species of family Psittacidae in Brazil

Disfunção ventricular direita e rejeição em transplante cardíaco

Background: The practice of screening for complications has provided high survival rates among heart transplantation (HTx) recipients. Objectives: Our aim was to assess whether changes in left ventricular (LV) and right ventricular (RV) global longitudinal strain (GLS) are associated with cellular rejection. Methods: Patients who underwent HTx in a single center (2015 – 2016; n = 19) were included in this retrospective analysis. A total of 170 biopsies and corresponding echocardiograms were evaluated. Comparisons were made among biopsy/echocardiogram pairs with no or mild (0R/1R) evidence of cellular rejection (n = 130 and n = 25, respectively) and those with moderate (2R) rejection episodes (n=15). P-values < 0.05 were considered statistically significant Results: Most patients were women (58%) with 48 ± 12.4 years of age. Compared with echocardiograms from patients with 0R/1R rejection, those of patients with 2R biopsies showed greater LV posterior wall thickness, E/e’ ratio, and E/A ratio compared to the other group. LV systolic function did not differ between groups. On the other hand, RV systolic function was more reduced in the 2R group than in the other group, when evaluated by TAPSE, S wave, and RV fractional area change (all p < 0.05). Furthermore, RV GLS (−23.0 ± 4.4% in the 0R/1R group vs. −20.6 ± 4.9% in the 2R group, p = 0.038) was more reduced in the 2R group than in the 0R/1R group. Conclusion: In HTx recipients, moderate acute cellular rejection is associated with RV systolic dysfunction as evaluated by RV strain, as well as by conventional echocardiographic parameters. Several echocardiographic parameters may be used to screen for cellular rejection.Fundamento: A prática de triagem para complicações tem proporcionado altas taxas de sobrevida entre pacientes que receberam transplante cardíaco (TC). Objetivos: Visamos avaliar se alterações no strain longitudinal global (SLG) do ventrículo esquerdo (VE) e do ventrículo direito (VD) estão associadas à rejeição celular. Métodos: Pacientes que foram submetidos à TC em um único centro (2015 – 2016; n = 19) foram incluídos nesta análise retrospectiva. Foram avaliados um total de 170 biópsias com ecocardiogramas correspondentes. Foram realizadas comparações entre pares de biópsia/ecocardiograma com nenhuma ou leve (0R/1R) evidência de rejeição celular (n = 130 e n = 25, respectivamente) e aqueles com episódios de rejeição moderada (2R) (n = 15). Foram considerados estatisticamente significativos os valores de p < 0,05. Resultados: A maioria dos pacientes eram mulheres (58%) com idade média de 48 ± 12,4 anos. Em comparação com os ecocardiogramas dos pacientes com rejeição 0R/1R, os pacientes com biópsias 2R apresentaram maior espessura da parede posterior do VE, relação E/e’ e relação E/A, em comparação com o outro grupo. A função sistólica do VE não diferiu entre os grupos. Por outro lado, a função sistólica do VD foi reduzida no grupo 2R em comparação ao outro grupo, quando avaliada por TAPSE, onda S e variação fracional da área do VD. Adicionalmente, SLG VD (−22,97 ± 4,4% no grupo 0R/1R vs. −20,6 ± 4,9% no grupo 2R, p = 0,038) foi reduzido no grupo 2R, em comparação com o grupo 0R/1R. Conclusão: Em pacientes de TC, rejeição celular aguda moderada está associada à disfunção sistólica do VD, avaliado pelo strain do VD, bem como por parâmetros ecocardiográficos convencionais. Vários parâmetros ecocardiográficos podem ser utilizados para realizar triagem para rejeição celular

Perfluorinated Alcohols at High Pressure: Experimental Liquid Density and Computer Simulations

The liquid density of five liquid 1H,1H-perfluorinated alcohols (CF3(CF2)n−1CH2OH n = 2, 3, 4, 5, 6) was measured as a function of pressure (0.1−70 MPa) and temperature (293.15−313.15 K). The corresponding isothermal compressibility and isobaric thermal expansivity coefficients were calculated from the experimental data. The results are compared with data from the literature for the equivalent hydrogenated alcohols. Atomistic molecular dynamics simulations were also performed, providing molecular-level insight into the experimental results, in particular about the H-bond network of the perfluorinated alcohols and the effect of pressure on the organization of the liquid

Actividad de acetilcolinesterasa y niveles totales de antioxidantes en perros con tumores de mama antes y después de la extirpación quirúrgica

Objective. The aim of this study was to evaluate AChE activity in total blood and the FRAP levels in samples from dogs with mammary tumors before and after surgery, as well as the relationship between these variables with immunohistochemical markers of tumor (E-caderina, ki-67, COX-2). Materials and methods. In this study, 13 dogs with mammary tumors were divided into two groups (A and B). The group A was formed by dogs with tumors smaller than 3 cm of diameter, and the group B was formed by dogs with tumor of 3 cm of diameter or larger. The AChE activity and FRAP levels were evaluated before and after surgery and the immunohistochemistry were performed at the tumors. Results. The AChE activity was significantly increased (p&lt;0.05) in dogs with mammary cancer compared to control animals, and neither surgery or tumor size affected the AChE activity (p&gt;0.05). FRAP levels before surgery were significantly lower (p&lt;0.05) compared to control animals. Also, FRAP levels increased significantly after surgery in animals of the group A compared to data before surgery, a fact not observed in dogs from the group B. E-cadherin showed low significant positive correlation with FRAP levels (r=0.37, P-value=0.05); COX-2 showed a moderate significant positive correlation to FRAP (r=0.55, P-value&lt;0.05); and COX-2 showed a low significant positive correlation to AChE (r=0.32, P-value=0.01). Conclusions. AChE and antioxidant levels are modified in dogs with mammary cancer. These variables are involved in various physiological functions, and thus, they might be related to disease pathogenesis.Objetivo. El objetivo de este estudio fue evaluar la actividad de la AChE en sangre total y los niveles de FRAP en muestras de perros con tumores mamarios antes y después de la cirugía, así como la relación entre estas variables con marcadores inmunohistoquímicos de tumores (E-caderina, ki-67 , COX - 2). Materiales y métodos. En este estudio, 13 perros con tumores mamarios se dividieron en dos grupos (A y B). El grupo A estaba formado por perros con tumores menores de 3 cm de diámetro y el grupo B estaba formado por perros con tumor de 3 cm de diámetro o más. La actividad de AChE y los niveles de FRAP se evaluaron antes y después de la cirugía y la inmunohistoquímica se realizó en los tumores. Resultados. La actividad de la AChE aumentó significativamente (p &lt;0,05) en perros con cáncer mamario en comparación con los animales control, y ni la cirugía ni el tamaño tumoral afectaron la actividad de la AChE (p&gt; 0,05). Los niveles de FRAP antes de la cirugía fueron significativamente más bajos (p &lt;0,05) en comparación con los animales control. Además, los niveles de FRAP aumentaron significativamente después de la cirugía en animales del grupo A en comparación con los datos antes de la cirugía, hecho que no se observó en perros del grupo B. La E-cadherina mostró correlación positiva baja con los niveles de FRAP (r = 0,37, valor P = 0,05); COX-2 mostró una moderada correlación positiva significativa con FRAP (r = 0,55, P-valor &lt;0,05); Y la COX-2 mostró una correlación positiva de baja significación con la AChE (r = 0.32, P-valor = 0.01). Conclusiones. AChE y los niveles de antioxidantes se modifican en perros con cáncer de mama. Estas variables están implicadas en diversas funciones fisiológicas, y por lo tanto, pueden estar relacionadas con la patogénesis de la enfermedad

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca